The primary endpoint, response in functional disability, was observed in 54 percent of subjects treated with Gamunex (2g/kg loading dose, followed by 1g/kg ...
Research Triangle Park, North Carolina — Pharmaceutical manufacturer, Talecris Biotherapeutics, Inc., has said that future products in its Gamunex range ...